These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36764041)

  • 1. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP).
    Rizzo M; Colletti A; Penson PE; Katsiki N; Mikhailidis DP; Toth PP; Gouni-Berthold I; Mancini J; Marais D; Moriarty P; Ruscica M; Sahebkar A; Vinereanu D; Cicero AFG; Banach M;
    Pharmacol Res; 2023 Mar; 189():106679. PubMed ID: 36764041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence.
    Cicero AFG; Colletti A; Bellentani S
    Nutrients; 2018 Aug; 10(9):. PubMed ID: 30142943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease.
    Del Ben M; Polimeni L; Baratta F; Pastori D; Angelico F
    Br J Clin Pharmacol; 2017 Jan; 83(1):88-95. PubMed ID: 26852185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
    Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
    Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
    Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
    Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals.
    Della Pepa G; Vetrani C; Lombardi G; Bozzetto L; Annuzzi G; Rivellese AA
    Nutrients; 2017 Sep; 9(10):. PubMed ID: 28954437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Non-alcoholic fatty liver disease; a full-bodied epidemic].
    Tushuizen ME; Holleboom AG; Koot BGP; Blokzijl H; van Mil SWC; Koek GH
    Ned Tijdschr Geneeskd; 2020 Feb; 164():. PubMed ID: 32267638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to Reduce Cardiovascular Risk in Nonalcoholic Fatty Liver Disease.
    Ismaiel A; Dumitrascu DL
    Am J Ther; 2023 May; 30(3):e242-e256. PubMed ID: 32467498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
    Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
    Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-alcoholic fatty liver disease.
    Powell EE; Wong VW; Rinella M
    Lancet; 2021 Jun; 397(10290):2212-2224. PubMed ID: 33894145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment.
    Che W; Zhao M; Li X; Li C; Cho WC; Yu S
    Front Endocrinol (Lausanne); 2022; 13():1002916. PubMed ID: 36523601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease.
    Konyn P; Ahmed A; Kim D
    Clin Mol Hepatol; 2023 Feb; 29(Suppl):S43-S57. PubMed ID: 36417893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.
    Lombardi R; Onali S; Thorburn D; Davidson BR; Gurusamy KS; Tsochatzis E
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011640. PubMed ID: 28358980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease.
    Hassen G; Singh A; Belete G; Jain N; De la Hoz I; Camacho-Leon GP; Dargie NK; Carrera KG; Alemu T; Jhaveri S; Solomon N
    Cureus; 2022 May; 14(5):e25495. PubMed ID: 35783879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
    Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
    J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.